SETDB1 antibody (AA 20-871)

Catalog No. ABIN7871887

The Rabbit Polyclonal anti-SETDB1 antibody (ABIN7871887) specifically detects SETDB1 in WB, ELISA and FACS. The antibody is reactive with Human samples.

Quick Overview for SETDB1 antibody (AA 20-871) (ABIN7871887)

Target: SETDB1 (SET Domain, Bifurcated 1 (SETDB1))

Reactivity: Human

Host: Rabbit

Clonality: Polyclonal

Conjugate: This SETDB1 antibody is un-conjugated

Application: Western Blotting (WB), ELISA, Flow Cytometry (FACS)

Product Details anti-SETDB1 Antibody

Binding Specificity: AA 20-871

Purpose: SETDB1 Antibody / Histone-lysine N-methyltransferase SETDB1

Purification: Immunogen affinity purified

Immunogen: E.coli-derived human SETDB1 recombinant protein (Position: E20-E871) was used as the immunogen for the SETDB1 antibody.

Isotype: IgG

Application Details

Application Notes: Optimal dilution of the SETDB1 antibody should be determined by the researcher.

Restrictions: For Research Use only

Handling

Format: Lyophilized

Reconstitution: Adding 0.2 mL of distilled water will yield a concentration of 500 μg/mL

Buffer: Each vial contains 4 mg Trehalose, 0.9 mg NaCl, 0.2 mg Na2HPO4.

Storage: 4 °C,-20 °C

Storage Comment: After reconstitution, the SETDB1 antibody can be stored for up to one month at 4oC. For long-term, aliquot and store at -20oC. Avoid repeated freezing and thawing.

Target Details for SETDB1

Target: SETDB1 (SET Domain, Bifurcated 1 (SETDB1))

Alternative Name: SETDB1

Background: SETDB1 antibody detects Histone-lysine N-methyltransferase SETDB1, an enzyme responsible for methylating histone H3 at lysine 9 (H3K9), a key epigenetic mark associated with transcriptional repression and heterochromatin formation. Encoded by the SETDB1 gene on chromosome 1q21.3, this nuclear protein is part of the SET domain-containing family of histone methyltransferases and plays a central role in chromatin remodeling, gene silencing, and genome stability.

SETDB1 contains a SET domain conferring methyltransferase activity, a methyl-CpG-binding domain (MBD), and a tudor domain that facilitate chromatin targeting. It forms complexes with co-repressors such as KAP1 (TRIM28) and HP1, directing H3K9 trimethylation at retroelements, developmental genes, and repetitive sequences. Through this mechanism, SETDB1 maintains transcriptional repression and contributes to X-chromosome inactivation, embryonic stem cell identity, and defense against endogenous retroviral elements.

The SETDB1 antibody is widely used in epigenetics, developmental biology, and cancer research to examine histone methylation and transcriptional silencing. Western blot analysis identifies a 170 kilodalton band corresponding to SETDB1, while immunofluorescence reveals punctate nuclear staining colocalizing with heterochromatin regions. This antibody enables researchers to assess chromatin states, epigenetic modifications, and silencing pathways across diverse cell types.

Aberrant SETDB1 expression and activity have been linked to multiple cancers, including melanoma, glioma, and lung carcinoma, where it promotes oncogenic transcriptional reprogramming and genomic instability. SETDB1 overexpression can also suppress immune responses by silencing interferon-stimulated genes. The SETDB1 antibody provides a precise reagent for studying epigenetic repression, gene regulation, and chromatin-based disease mechanisms. NSJ Bioreagents validates this antibody for its applications, ensuring high specificity for epigenetic and transcriptional research.

UniProt: Q15047